Uncategorized – Page 25

This major investment demonstrates J&J’s commitment to expanding its U.S. manufacturing and innovation capabilities, with potential benefits for job creation and the domestic pharmaceutical industry. The announcement aligns with broader trends of increased U.S. manufacturing investment by large corporations in recent years.

Alnylam’s Amvuttra Approved for ATTR Cardiomyopathy, Challenging Pfizer and BridgeBio

1 month ago talkbio0Tagged Amvuttra, Approved, ATTR-CM, Cardiomyopathies, RNA Interference, United States Food and Drug Administration

Amvuttra, vutrisiran, ATTR-CM, FDA approval, RNAi therapeutic, cardiomyopathy

MacroGenics Discontinues Development of Vobra Duo ADC After Phase 2 Prostate Cancer Trial Results

1 month ago talkbio0Tagged Antibody-Drug Conjugates, CD276 gene, concerns, development aspects, discontinued, Larix, MacroGenics, Malignant neoplasm of prostate, Safety, vobra

MacroGenics, vobra duo, antibody-drug conjugate, B7-H3, prostate cancer, TAMARACK trial, discontinued development, safety concerns

Adaptimmune, after bringing cell therapy to market, questions viability and defunds 2 preclinical programs

1 month ago talkbio0Tagged Adaptimmune, cellular targeting, Market, Solid Neoplasm, Tecelra, Viable

Adaptimmune, Tecelra, Viable, Market, Solid Neoplasm, cellular targeting

A closer look at pharmas top patent losses in 2025

1 month ago talkbio0Tagged 2023, 2025, Bayer, competition, Expiration, function, Impact food supplement, Indication of (contextual qualifier), Legal patent, Market, Patent Cliff, Regeneron, Sales - occupational activity

Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023